 The planned number of patients is a total of 144 based on 36 enrolled into each of 4 treatment arms. The target population are patients with breast cancer who are candidates for neoadjuvant or adjuvant treatment with TC chemotherapy. All patients who receive at least 1 dose of either HM10460A or pegfilgrastim will be followed for safety through 20 2 days after their last dose of study treatment or until all treatment-related AEs have resolved or returned to baselineGrade 1, whichever is longer, or until it is determined that the outcome will not change with further follow-up. 